BerGenBio

News

Genmab axes development of AXL-targeting cancer drug enapota...

Genmab has axed development of its pipeline cancer drug enapotamab vedotin after it failed to show enough activity in a proof-of-concept trial.

News

BerGenBio raises 45 million euros for COVID-19 drug developm...

Norway’s BerGenBio has raised 500 million Norwegian kroner – around $45.4 million euros – in an oversubscribed private placement to develop its pipeline that includes a potential COVID-19 t

News

UK initiative aims to cut COVID-19 drug development to a few...

A new UK trial initiative aims to cut the design phase of clinical studies for potential COVID-19 drugs from around 18 months to a few weeks.

Genmab axes development of AXL-targeting cancer drug enapota...

BerGenBio raises 45 million euros for COVID-19 drug developm...

UK initiative aims to cut COVID-19 drug development to a few...

On the benefits of earlier oncological intervention, with Jo...

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks